The CHANCE programme gave clinicians stronger evidence on when to use short-term dual antiplatelet therapy after minor stroke or TIA, and how genetic testing could support more personalised treatment. BMJ Impact Analytics enabled the researchers to demonstrate how these findings had informed clinical guidance and policy across 62 countries, providing a broader picture than academic citation counts alone. The CHANCE programme of clinical trials, 75 led by Professor Yongjun Wang, president of Beijing Tiantan Hospital and the Chinese Stroke Association, generated important evidence on how that risk could be reduced. The studies showed that short term dual antiplatelet therapy reduced recurrent stroke risk and later demonstrated how genetic testing could guide more personalised treatment. Stroke studies from China shape global guidance A landmark programme of stroke research published in The BMJ, Stroke and Vascular Neurology, and The New England Journal of Medicine helped establish new approaches to preventing recurrent stroke after minor stroke and transient ischaemic attack (TIA). Analysis from BMJ Impact Analytics demonstrated the extent to which the wider CHANCE * research programme had informed clinical guidance and health policy worldwide. Stroke affects around 15 million people worldwide each year and remains one of the leading causes of death and long term disability. 73 Effective prevention strategies are a global clinical priority. 74 People who experience a minor stroke or TIA face a heightened risk of a subsequent stroke, making timely and effective secondary prevention critical.
BMJ Impact Analytics reveals the programme's global influence: 76 57 citations in clinical guidelines and health policy documents from CHANCE-related papers collectively 14 years of CHANCE research (2009–2023) 5,000+ patients enrolled at 114 centres in China in the original CHANCE trial 77 62 countries citing Chinese stroke research in policy and guidance documents Research was cited by NICE, the WHO, the American Academy of Neurology, and the European Stroke Organisation The CHANCE programme has made an important contribution to our understanding of how best to prevent recurrent stroke after minor stroke or TIA. Its influence on clinical guidance internationally demonstrates the value of rigorous clinical research, especially large randomised
controlled trials, in informing and improving patient care around the world.” Philip Bath, Professor of stroke medicine and CHANCE-2 investigator, University of Nottingham, UK
*Clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE)
27
Powered by FlippingBook